{"id":"allocetra","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T05:52:28.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06233474","phase":"PHASE1, PHASE2","title":"Study of Intra-articular Allocetra in Knee Osteoarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2024-01-26","conditions":"Osteoarthritis, Knee","enrollment":160},{"nctId":"NCT06522035","phase":"PHASE1","title":"Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis","status":"RECRUITING","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2024-08-01","conditions":"Arthritis, Psoriatic","enrollment":6},{"nctId":"NCT04612413","phase":"PHASE2","title":"A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients","status":"COMPLETED","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2020-11-30","conditions":"Sepsis, Community-acquired Pneumonia, Urinary Tract Infections","enrollment":148},{"nctId":"NCT06208241","phase":"EARLY_PHASE1","title":"Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amir Oron","startDate":"2023-07-12","conditions":"Knee Osteoarthritis","enrollment":18},{"nctId":"NCT06748651","phase":"PHASE1","title":"Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)","status":"RECRUITING","sponsor":"Dr. Amit Druyan","startDate":"2024-12-15","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":6},{"nctId":"NCT06459063","phase":"PHASE1, PHASE2","title":"Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint","status":"RECRUITING","sponsor":"Kaplan Medical Center","startDate":"2024-06-10","conditions":"Osteoarthritis Thumb","enrollment":46},{"nctId":"NCT05581719","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy","status":"TERMINATED","sponsor":"Enlivex Therapeutics RDO Ltd.","startDate":"2022-11-15","conditions":"Solid Tumor, Peritoneal Metastases, Peritoneal Cancer","enrollment":14},{"nctId":"NCT05431907","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis","status":"TERMINATED","sponsor":"Enlivex Therapeutics RDO Ltd.","startDate":"2022-06-29","conditions":"Peritoneal Metastases","enrollment":9},{"nctId":"NCT04922957","phase":"PHASE2","title":"A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)","status":"TERMINATED","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2021-09-01","conditions":"Covid19","enrollment":12},{"nctId":"NCT04659304","phase":"PHASE1","title":"Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19","status":"UNKNOWN","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2021-12","conditions":"Covid19","enrollment":18},{"nctId":"NCT04590053","phase":"PHASE2","title":"Allocetra-OTS in COVID-19, Phase II","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2020-10-20","conditions":"Covid19","enrollment":24},{"nctId":"NCT04513470","phase":"PHASE1","title":"Allocetra-OTS in COVID-19","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2020-08-01","conditions":"COVID-19","enrollment":5},{"nctId":"NCT03925857","phase":"PHASE1","title":"Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS","status":"COMPLETED","sponsor":"Enlivex Therapeutics Ltd.","startDate":"2019-01-27","conditions":"Organ Dysfunction Syndrome Sepsis","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Allocetra","genericName":"Allocetra","companyName":"Enlivex Therapeutics Ltd.","companyId":"enlivex-therapeutics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}